Efficacy and safety of PD-1/PD-L1 inhibitor combined with chemotherapy versus chemotherapy alone in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis

BACKGROUND: There is increasing evidence that immunotherapy (programmed cell death-1 (PD-1) inhibitor) combined with chemotherapy is superior to chemotherapy alone in neoadjuvant therapy for patients with previously untreated, unresectable advanced, or metastatic esophageal adenocarcinoma (EAC)/gast...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Bo-Wei, Shang, Qi-Xing, Yang, Yu-Shang, Chen, Long-Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129365/
https://www.ncbi.nlm.nih.gov/pubmed/37114136
http://dx.doi.org/10.3389/fonc.2023.1077675

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129365/
https://www.ncbi.nlm.nih.gov/pubmed/37114136
http://dx.doi.org/10.3389/fonc.2023.1077675

Ejemplares similares